Hong Kong Biotech Stock News

3SBio (SEHK:1530) just released full year 2025 results, reporting sales of CNY 17,695.75 million and net income of CNY 8,482.16 million, drawing fresh attention to the stock’s recent move. See our latest analysis for 3SBio. The earnings release follows a board meeting earlier in March that highlighted these results and a potential final dividend. The strong full year figures appear to align with fresh interest in the stock, with a 7 day share price return of 13.25% and a 1 year total...

COSCO SHIPPING Holdings (SEHK:1919) reported full year 2025 results showing softer revenue and earnings, with sales of CNY 219.18b and net income of CNY 30.87b, shaping how investors reassess the container shipping group. See our latest analysis for COSCO SHIPPING Holdings. Despite softer revenue and earnings, COSCO SHIPPING Holdings' 1-day share price return of 1.33% and 90-day share price return of 9.16% come alongside a 1-year total shareholder return of 41.43% and very large 5-year gains,...

Recent performance snapshot for FWD Group Holdings FWD Group Holdings (SEHK:1828) has seen its share price weaken recently, with a 2.1% decline over the past day, smaller losses over the past week, and deeper falls over the past month and the past 3 months. See our latest analysis for FWD Group Holdings. With the share price at HK$30.16, FWD Group Holdings has a 30 day share price return of 18.5% and a 90 day share price return of 20.6%, suggesting momentum has been fading compared with the...

China Modern Dairy Holdings (SEHK:1117) has drawn fresh attention after releasing its full year 2025 results, reporting lower net losses alongside reduced sales, and reshaping its board and capital structure on the same date. See our latest analysis for China Modern Dairy Holdings. The latest results and board changes have landed after a weak few months for the share price, with a 90 day share price return of negative 10.76% and year to date share price return of negative 12.96%. However, a 1...

Why Yadea Group Holdings Stock Is Back on Investors’ Radar Yadea Group Holdings (SEHK:1585) has drawn fresh attention after reporting full year 2025 results, with sales of CNY 37,008.24 million and net income of CNY 2,911.59 million, both higher than the prior year. See our latest analysis for Yadea Group Holdings. The earnings release on 30 March appears to have coincided with a sharp pickup in momentum, with a 1-day share price return of 5.19% and a 30-day share price return of 11.92%...

WEILONG Delicious Global Holdings (SEHK:9985) has drawn fresh attention after reporting full year 2025 results, with sales of CN¥7,223.76 million and net income of CN¥1,425.2 million compared to the prior year. See our latest analysis for WEILONG Delicious Global Holdings. The latest full year earnings arrived after a weak run for shareholders, with the 1 year total shareholder return at a 34.02% loss and the 30 day share price return at a 17.34% loss, while the 3 year total shareholder...

Huishang Bank (SEHK:3698) has drawn fresh attention after reporting its full year 2025 earnings. The bank recorded net income of CN¥16,524.6 million and earnings per share of CN¥1.14 from continuing operations. See our latest analysis for Huishang Bank. The full year 2025 earnings release and the recent board meeting around the dividend appear to have coincided with stronger sentiment, with Huishang Bank’s 90 day share price return of 43.75% and 1 year total shareholder return of 85.38%...

Anton Oilfield Services Group (SEHK:3337) closed FY 2025 with fourth quarter revenue of C¥1.9b and net income of C¥143.2m, while trailing twelve month revenue came in at C¥5.6b with net income of C¥373.1m and EPS of C¥0.137. Over recent periods the company has seen quarterly revenue move from C¥1.1b in the third quarter of 2024 to C¥1.3b in the second quarter of 2025 and then to C¥1.9b in the fourth quarter of 2025. Over the same stretch, net income has ranged from C¥52.9m to C¥143.2m, with...

InSilico Medicine Cayman TopCo (SEHK:3696) has opened FY 2025 with first half revenue of US$27.5 million and a basic EPS loss of US$0.25, while trailing twelve month figures show revenue of US$56.2 million alongside a net loss of US$352.3 million and EPS of US$4.48 in the red. Over the recent reported periods, the company has seen revenue shift from US$59.7 million in the first half of FY 2024 to US$26.1 million in the second half and then to US$27.5 million in the first half of FY 2025. Net...

Star Shine Holdings Group (SEHK:1440) has put investors on alert with fresh guidance pointing to a larger FY2025 net loss, just ahead of its March 30 results announcement and the related board meeting. See our latest analysis for Star Shine Holdings Group. The earnings warning has shifted sentiment sharply in the short term, with a 10.83% 1 day share price return decline and a 6.38% 7 day pullback, despite a strong 90 day share price return of 89.75% and a very large 5 year total shareholder...

China Resources Pharmaceutical Group (SEHK:3320) has come into focus after reporting full year 2025 results and hosting its earnings call, alongside a Board proposal to lift the final cash dividend compared with 2024. See our latest analysis for China Resources Pharmaceutical Group. The earnings release and higher proposed dividend appear to have coincided with a sharp improvement in sentiment, with a 7 day share price return of 28.67% and a 30 day share price return of 25.27% helping lift...

Hansoh Pharmaceutical Group (SEHK:3692) just posted its FY 2025 first half results with revenue of C¥7.4b and basic EPS of C¥0.53, against a trailing twelve month backdrop of C¥15.0b in revenue and C¥0.93 in EPS off C¥5.6b in net income, as well as earnings growth of 27.1% over the past year. The company has seen revenue move from C¥6.5b and EPS of C¥0.46 in 1H FY 2024 to C¥5.8b and EPS of C¥0.28 in 2H FY 2024, and now to C¥7.4b and EPS of C¥0.53 in 1H FY 2025. This sets up a story where rich...

Kindstar Globalgene Technology (SEHK:9960) has reported its FY 2025 first half results with revenue of C¥456.9 million and a basic EPS loss of C¥0.0378, while trailing 12 month figures show revenue of C¥933.6 million and a basic EPS loss of C¥0.0592. Over the past three half year periods, revenue has moved from C¥473.3 million in 1H 2024 to C¥454.2 million in 2H 2024 and C¥456.9 million in 1H 2025, alongside a shift in basic EPS from C¥0.0125 to a loss of C¥0.0706 and then a smaller loss of...

Fosun International share performance snapshot Fosun International (SEHK:656) has drawn investor attention after recent share price moves, with the stock showing a 2.2% decline over the past day but gains over the past week and month. See our latest analysis for Fosun International. That 2.2% one-day share price decline comes after a 9.5% seven-day share price return and a weaker one-year total shareholder return of a 2.7% decline, which suggests recent momentum contrasts with longer-term...

Jiangsu Expressway (SEHK:177) has wrapped up FY 2025 with fourth quarter revenue of C¥7.3b and basic EPS of C¥0.15, alongside trailing twelve month revenue of C¥20.3b and EPS of C¥0.91 that sit against an improved net margin of 22.6% compared with 21.3% a year earlier. Over recent periods, revenue has ranged from C¥3.6b to C¥9.1b per quarter while quarterly EPS has moved between C¥0.15 and C¥0.28, giving investors a clear view of how earnings track the top line across the year. With that...

What China XLX Fertiliser’s latest earnings mean for investors China XLX Fertiliser (SEHK:1866) just released its 2025 annual results, pairing modest profit growth after non recurring items with a 23.1% dividend increase, an improved borrowing mix, and ongoing expansion of new production bases. See our latest analysis for China XLX Fertiliser. The earnings release has arrived alongside a sharp 9.5% 1 day share price return, adding to a 90 day share price return of 28.2% and a very large 1...

PetroChina (SEHK:857) has laid out a steady set of FY 2025 numbers, with fourth quarter revenue at C¥695.2b and basic EPS of C¥0.17, while trailing twelve month revenue stands at C¥2.86t and EPS at C¥0.86. Over recent periods the company has seen quarterly revenue move between C¥681.7b and C¥753.1b and basic EPS range from C¥0.17 to C¥0.26. This gives you a clear view of how the top line and per share earnings have tracked into the latest print. With a trailing net profit margin near the mid...

Zhongyu Energy Holdings (SEHK:3633) opened FY 2025 with first half revenue of about HK$6.6b and basic EPS of HK$0.089, setting a cleaner profit picture against a share price of HK$2.68. The company reported revenue of roughly HK$7.3b in 1H 2024 and HK$6.6b in 1H 2025, while basic EPS moved from HK$0.086 in 1H 2024 to HK$0.089 in the latest period. This leaves investors with a results set where modest EPS progress sits alongside a relatively slim earnings margin profile. See our full analysis...

Goodbaby International Holdings (SEHK:1086) FY 2025 earnings snapshot Goodbaby International Holdings (SEHK:1086) has released its FY 2025 numbers with first half revenue of HK$4.3b and basic EPS of HK$0.06. This provides context for how you might weigh the latest results against the share price of HK$0.99. Over recent periods, the company has reported revenue between HK$4.2b and HK$4.6b per half, while basic EPS ranged from HK$0.11 to HK$0.06, giving a clear view of how the top line and per...

Xinte Energy (SEHK:1799) has reported FY 2025 first half revenue of C¥7.3b with a basic EPS loss of C¥0.18, while trailing twelve month revenue sits at C¥15.3b against a basic EPS loss of C¥0.84. Over recent periods, the company has seen revenue move from C¥11.7b in 1H 2024 to C¥9.5b in 2H 2024 before landing at C¥7.3b in 1H 2025, with basic EPS losses of C¥0.62, C¥2.11 and C¥0.18 respectively. Investors are likely to focus on how these headline numbers compare with expectations around...

Jinshang Bank (SEHK:2558) has put fresh numbers on the table for FY 2025, with first half revenue of C¥1.96b and basic EPS of C¥0.18 setting the tone for how the rest of the year may be judged. Over recent periods the bank has seen revenue move between C¥1.96b and C¥2.16b per half year, while basic EPS has ranged from C¥0.12 to C¥0.18. This gives you a clear view of how the income line and per share earnings have been tracking into this latest report. With a net profit margin in the low 40s...

China Risun Group (SEHK:1907) has reported FY 2025 first half revenue of C¥20.5b and basic EPS of C¥0.0066, with the latest twelve month figures showing revenue of C¥39.3b and basic EPS of C¥0.013. The company has seen revenue move from C¥25.2b in the first half of 2024 to C¥22.3b in the second half of 2024 and then to C¥20.5b in the first half of 2025. Over the same periods, basic EPS shifted from C¥0.025383 to a loss of C¥0.021219 and then to C¥0.0066, setting up an earnings story that now...

Event context and recent share performance Ascentage Pharma Group International (SEHK:6855) has attracted investor attention recently, with the share price moving 7.5% over the past week and 7.5% over the past month, against a small decline in the past 3 months. Over a longer horizon, the stock shows a negative year to date return, alongside a 6.9% 1 year total return. This gives investors a mixed backdrop to assess the company’s clinical stage biotech profile and current valuation...

Innovent Biologics (SEHK:1801) has drawn investor attention after recent share price moves, with the stock up 7.7% over the past day and 5.5% over the past week, inviting a closer look at its current valuation. See our latest analysis for Innovent Biologics. That 7.7% 1 day share price return and 8.5% year to date share price return sit against a 1 year total shareholder return of 85.1% and a 3 year total shareholder return of 143.2%, suggesting momentum has been building over time as the...